Outcomes of Cardiac Transplantation in Highly Sensitized Pediatric Patients
Tóm tắt
Despite aggressive immunosuppressive therapy, pediatric orthotopic heart transplant (OHT) candidates with elevated pre-transplant panel reactive antibody (PRA) carry an increased risk of rejection and early graft failure following transplantation. This study has aimed to more specifically evaluate the outcomes of transplant candidates stratified by PRA values. Records of pediatric patients listed for OHT between April 2004 and July 2008 were reviewed (n = 101). Survival analysis was performed comparing patients with PRA < 25 to those with PRA > 25, as well as patients with PRA < 80 and PRA > 80. Patients with PRA > 25 had decreased survival compared with those with PRA < 25 after listing (P = 0.004). There was an even greater difference in survival between patients with PRA > 80 and those with PRA < 80 (P = 0.002). Similar analyses for the patients who underwent successful transplantation showed no significant difference in post-transplant survival between patients with a pre-transplant PRA > 25 and those with PRA < 25 (P = 0.23). A difference approaching significance was noted for patients with PRA > 80 compared with PRA < 80 (P = 0.066). Patients with significantly elevated pre-transplant PRAs at the time of listing have a significantly worse outcome compared to those with moderately increased PRA values or non-sensitized patients. Further study is necessary to guide physician and family treatment decisions at the time of listing.
Tài liệu tham khảo
Behr TM, Feucht AE, Richter K, Reiter C, Spes CH, Pongratz D et al (1999) Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment Cd4 in endomyocardial biopsies. J Heart Lung Transpl 18:112–904
Casaez TW, Perens GP, Williams RJ, Kutay E, Fishbein MC, Reed EF et al (2007) Humoral rejection in pediatric orthotopic heart transplant. J Heart Lung Transpl 26:114–119
Feingold B, Bowman P, Zeevi A, Girnita AL, Quivers ES, Miller SA et al (2007) Survival in allosensitized children after listing for cardiac transplantation. J Heart Lung Transpl 26:565–571
Jacobs JP, Quintessenza JA, Boucek RJ, Morell VO, Botero LM, Badhwar V et al (2004) Pediatric cardiac transplantation in children with high panel reactive antibody. Ann Thorac Surg 78:1703–1709
Leman NR, Levi DS, Alejos JC, Wetzel GT (2005) Predictors of graft longevity in pediatric heart transplantation. Pediatr Cardiol 26:762–767
Lones MA, Czer LS, Trento A, Harasty D, Miller JM, Fishbein MC (1995) Clinical pathologic features of humoral rejection in cardiac allografts a study of 81 consecutive patients. J Heart Lung Transpl 14:151–162
Mahle WT, Vincent RN, Kanter KR (2005) Cardiac retransplantation in childhood: analysis of data from the United Network for Organ Sharing. J Thorac Cardiovasc Surg 130:542–546
McKenna DH Jr, Eastlund T, Segall M, Noreen HJ, Park S (2002) HLA alloimmunization in patients requiring ventricular assist device support. J Heart Lung Transpl 21:1218–1224
Michaels PJ, Espejo ML, Kobashigawa J, Alejos JC, Burch C, Takemoto S (2003) Detection of humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transpl 22:58–69
Pollock-BarZiv SM, den Hollander N, Nan BY, Kantor P, McCrindle B, West LJ et al (2007) Pediatric heart transplantation in human leukocyte antigen-sensitized patients. Circulation 116(Suppl):I172–I178
Thompson JS, Thacker LR Jr, Takemoto S (2000) The influence of conventional and cross-reactive group HLA matching on cardiac transplant outcome: an analysis from the United Network of organ sharing scientific registry. Transplantation 69:2178–2186
Welters MJ, Oei FB, Witvliet MD, Vaessen LM, Cromme-Dijkhuis AH, Bogers AJ et al (2002) A broad and strong humoral immune response to donor HLA after implantation of cryopreserved human heart valve allografts. Hum Immunol 63:1019–1025
Wright EJ, Fiser WP, Edens E, Frazier EA, Morrow WR, Imamura M et al (2007) Cardiac transplant outcomes in pediatric patients with preformed anti-human leukocyte antigen antibodies and/or positive retrospective cross-match. J Heart Lung Transpl 26:1163–1169
Zangwill SD, Ellis TM, Zlotocha J, Jaquiss RD, Tweddell JS, Mussatto KA et al (2006) The virtual cross-match—a screening tool for sensitized pediatric heart transplant recipients. Pediatr Transpl 10(1):38–41
Holt DB, Lublin DM, Phelan DL, Boslaugh SE, Gandhi SK, Huddleston CB et al (2007) Mortality and morbidity in presensitized pediatric heart transplantation recipients with a positive donor cross-match utilizing peri-operative plasmaphoresis and cytolytic therapy. J Heart Lung Transpl 26:876–882